A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations
Latest Information Update: 22 Dec 2021
At a glance
- Drugs Perampanel (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Eisai Inc
- 30 Sep 2021 This trial has been completed in France (End Date: 27 Jun 2008), according to European Clinical Trials Database record.
- 10 May 2019 This trial has been completed in Italy, according to European Clinical Trials Database.
- 03 Jul 2012 Additional locations added as reported by European Clinical Trials Database.